Medical Conditions Treated with Cannabis UK: Full Guide

Complete Guide to Qualifying Medical Conditions for UK Cannabis Prescriptions

Medical cannabis has been a prescribed medication in the UK since November 2018, following the rescheduling of cannabis-based products for medicinal use. This comprehensive guide outlines all recognised qualifying conditions, evidence levels, prescribing practices, and practical information for patients and healthcare professionals.

Introduction and Legal Framework

In the UK, cannabis-based products for medicinal use (CBPMs) can only be prescribed by specialist doctors in specific circumstances. The NHS initially restricted prescribing to three conditions: epilepsy, multiple sclerosis spasticity, and chemotherapy-induced nausea and vomiting. However, specialist clinicians can prescribe for other conditions where conventional treatments have failed, documented as “unlicensed” or “off-label” prescribing.

Private clinics now offer prescribing services for a wider range of conditions, though costs are typically £300-600 for consultations plus £150-400 monthly for medication. Understanding which conditions have supporting evidence and realistic treatment expectations is essential before pursuing cannabis-based treatment.

Chronic Pain Conditions

Neuropathic Pain (Peripheral Neuropathy, Post-Herpetic Neuralgia)

Neuropathic pain affects millions in the UK and represents one of the most commonly treated conditions with medical cannabis in private practice.

Evidence Level: Moderate to High

Multiple systematic reviews and clinical trials support cannabinoid use for neuropathic pain. The 2017 National Academies of Sciences comprehensive review rated the evidence as “substantial” for cannabis or cannabinoids in treating chronic pain, particularly neuropathic forms. Patients often report significant relief after conventional treatments (gabapentin, pregabalin, amitriptyline) have proven inadequate.

Typical Prescription Profile:

• Starting dose: 5-10mg THC daily (often evening)
• Titration: Increase by 5mg every 3-5 days
• Maintenance: 15-40mg THC daily (divided doses)
• Duration: Ongoing, with regular 3-monthly reviews

Best Products:

Musculoskeletal Pain (Back Pain, Arthritis, Joint Pain)

Evidence Level: Moderate

Evidence supports cannabinoid use for chronic musculoskeletal pain, particularly for patients with inflammatory components (osteoarthritis, rheumatoid arthritis). Cannabis’s dual analgesic and anti-inflammatory properties make it attractive for these conditions. However, high-quality randomised controlled trials remain limited.

Typical Prescription Profile:

• Starting dose: 5mg THC daily
• Titration: Conservative increase due to older patient demographics often affected by these conditions
• Maintenance: 10-30mg THC daily
• Often combined with CBD 5-10mg for anti-inflammatory benefits

Best Products:

Fibromyalgia

Evidence Level: Moderate

Fibromyalgia’s complex neurobiological basis (altered pain processing, low endocannabinoid tone) theoretically supports cannabinoid treatment. Patient reports indicate improvements in widespread pain, fatigue, and sleep disturbance. However, clinical trial evidence remains limited compared to conventional treatments.

Typical Prescription Profile:

• Starting dose: 5-10mg THC + 5-10mg CBD
• Titration: Gradual increase (weekly) due to patient sensitivity
• Maintenance: 15-35mg THC daily plus 15-35mg CBD
• Evening dosing often preferred due to sleep benefits

Best Products:

Mental Health Conditions

Post-Traumatic Stress Disorder (PTSD)

Evidence Level: Moderate

PTSD represents one of the most promising mental health indications for cannabis. Research suggests cannabinoids reduce hyperarousal, facilitate fear extinction, and improve sleep. Multiple studies show THC and CBD working synergistically to reduce PTSD symptoms, with particular benefit for trauma-related nightmares and hypervigilance.

Typical Prescription Profile:

• Starting dose: 5mg THC + 5-10mg CBD daily
• Titration: Increase by 5mg THC weekly, titrating CBD separately
• Maintenance: 15-40mg THC + 20-40mg CBD daily
• Evening dosing standard, occasionally split morning and evening

Best Products:

Anxiety Disorders (Generalised Anxiety, Social Anxiety)

Evidence Level: Moderate

CBD shows strong anxiolytic properties in both preclinical and clinical research, with effect size comparable to benzodiazepines but without addiction potential. However, THC at higher doses may worsen anxiety in susceptible individuals, requiring careful dosing. Pure CBD or high CBD:THC ratios are preferred.

Typical Prescription Profile:

• Starting dose: 10-20mg CBD daily (minimal THC)
• Titration: Increase CBD by 10mg weekly
• Maintenance: 25-50mg CBD daily, THC 0-5mg
• Can be divided into morning and evening doses

Best Products:

Depression

Evidence Level: Low to Moderate

Evidence for cannabis in depression is mixed and cautious. While some studies suggest potential benefits, THC can worsen depression in some patients, particularly those with bipolar disorder. CBD may offer antidepressant properties, but large randomised controlled trials are lacking. Prescribing requires careful patient selection and monitoring.

Typical Prescription Profile:

• Starting dose: 5-10mg CBD + 2-5mg THC daily
• Titration: Very gradual, with close monitoring for mood changes
• Maintenance: 10-25mg CBD + 5-15mg THC daily (if tolerated)
• Often morning dosing to avoid evening sedation

Best Products:

Neurological Conditions

Epilepsy (Treatment-Resistant)

Evidence Level: High

Epilepsy is the first condition for which cannabis-derived medication received FDA approval (Epidiolex, pure CBD). In the UK, both NHS and private prescribers recognise epilepsy as a priority indication. CBD reduces seizure frequency in 40-50% of treatment-resistant patients, with effects often visible within weeks.

Typical Prescription Profile:

• Starting dose: 2.5-5mg CBD per kg body weight daily
• Titration: Increase by 2.5mg/kg weekly
• Maintenance: 10-20mg CBD per kg daily (divided doses)
• THC typically avoided; pure CBD products preferred
• Requires EEG monitoring and neurologist oversight

Best Products:

Multiple Sclerosis and Spasticity

Evidence Level: High

MS-related spasticity was one of three original NHS-approved indications. Cannabinoid-based medicines (particularly nabiximols/Sativex) have demonstrated efficacy in reducing spasticity severity in randomised controlled trials. Effects typically appear within 2-4 weeks.

Typical Prescription Profile:

• Starting dose: 2.7mg THC + 2.5mg CBD per dose (one spray)
• Initial frequency: 2-4 sprays daily, titrating weekly
• Maintenance: 4-12 sprays daily (typically split into 2-3 doses)
• Maximum 12 sprays daily according to Sativex licence

Best Products:

Parkinson’s Disease

Evidence Level: Moderate

Evidence for Parkinson’s is accumulating, with studies showing potential benefits for tremor, rigidity, bradykinesia, and sleep disturbance. Patient reports often describe substantial quality-of-life improvements, though controlled trials remain limited. Prescribing typically occurs in private practice.

Typical Prescription Profile:

• Starting dose: 2-5mg THC + 2-5mg CBD daily
• Titration: Conservative increase (5mg weekly) due to older patient age
• Maintenance: 10-30mg THC + 10-30mg CBD daily
• Evening dosing often preferred for sleep benefits
• Potential interactions with dopaminergic medications require monitoring

Best Products:

Gastrointestinal Conditions

Crohn’s Disease

Evidence Level: Moderate

Crohn’s disease evidence derives from both preclinical research demonstrating cannabinoid anti-inflammatory effects and patient reports of symptom improvement. Retrospective studies show improved quality-of-life scores in cannabis-using Crohn’s patients, though high-quality RCTs are limited. Benefits extend beyond pain relief to reduced diarrhoea and improved appetite.

Typical Prescription Profile:

• Starting dose: 5mg THC + 5mg CBD daily
• Titration: Increase by 5mg THC/CBD weekly
• Maintenance: 15-40mg THC + 15-40mg CBD daily
• Divided dosing preferred to maintain consistent anti-inflammatory effect

Best Products:

Ulcerative Colitis

Evidence Level: Moderate

Similar to Crohn’s, ulcerative colitis benefits from cannabinoid anti-inflammatory and gut-protective mechanisms. Evidence base is comparable to Crohn’s, with patient reports indicating improvements in inflammation markers, symptoms, and quality of life.

Typical Prescription Profile:

• Starting dose: 5-10mg THC + 5-10mg CBD daily
• Titration: Weekly increases by 5mg each cannabinoid
• Maintenance: 15-35mg THC + 15-35mg CBD daily
• Divided dosing (morning and evening) standard

Best Products:

Irritable Bowel Syndrome (IBS)

Evidence Level: Low to Moderate

IBS evidence is weaker than inflammatory bowel disease, though patient reports indicate symptom improvement in abdominal pain, bowel regularity, and bloating. The condition’s functional nature (without structural inflammation in most cases) may respond differently to cannabinoids than inflammatory conditions.

Typical Prescription Profile:

• Starting dose: 5mg THC + 5-10mg CBD daily
• Titration: Gradual increase due to gut sensitivity
• Maintenance: 10-25mg THC + 15-30mg CBD daily
• Evening dosing may be preferred

Best Products:

Sleep Disorders

Insomnia (Primary and Secondary)

Evidence Level: Moderate

Cannabis shows strong sedating properties, particularly THC, with effects on sleep latency and sleep architecture. Clinical and observational data support cannabinoid use for insomnia, particularly when secondary to pain or anxiety. However, long-term tolerance can develop, and cannabis may disrupt REM sleep architecture at higher doses.

Typical Prescription Profile:

• Starting dose: 5mg THC + 5-10mg CBD taken 1-2 hours before bed
• Titration: Increase THC by 5mg every 3-5 days
• Maintenance: 10-25mg THC + 5-15mg CBD nightly
• Single evening dose standard; timing important for sleep onset

Best Products:

Sleep Apnoea

Evidence Level: Low

Sleep apnoea presents complex challenges for cannabis prescribing. While cannabinoids may improve sleep-related anxiety, evidence regarding apnoea-hypopnoea index reduction is limited and contradictory. THC may potentially worsen respiratory events. Prescribing requires careful consideration and should not replace continuous positive airway pressure (CPAP) or standard treatment.

Typical Prescription Profile:

• Starting dose: 5mg CBD + 2-5mg THC nightly
• Titration: Very cautious; monitor for respiratory effects
• Maintenance: If prescribed at all, typically 5-15mg THC + 10-20mg CBD
• Never replace standard sleep apnoea treatment

Best Products:

Oncology (Cancer Pain and Chemotherapy Side Effects)

Cancer Pain

Evidence Level: Moderate to High

Cancer pain was one of three original NHS-approved indications. Cannabinoids provide analgesic benefits through multiple mechanisms: direct pain pathway modulation, reduced anxiety, and improved sleep. Particularly valuable as opioid-sparing strategy, reducing opioid requirements and associated side effects. Often part of multimodal pain management.

Typical Prescription Profile:

• Starting dose: 5-10mg THC + 5-10mg CBD daily
• Titration: Increase by 5mg weekly based on pain response
• Maintenance: 20-40mg
  

  Further Reading

  • Medical Cannabis UK — Complete Guide
  • Gorilla Glue #4 Strain — Effects, THC 25%+, UK Guide

Related Articles

• UK Medical Cannabis Strains Guide: All You Need to Know
• Medical Cannabis UK Costs: Complete Price Guide
• Medical Cannabis Exeter and Devon: Access Guide